• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 97

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

Psyence Group Announces Closing of Fourth Tranche of Private Placement and...

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA...

Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference...

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND...

Psychedelics Weekly – Investors Form REIT for Psychedelic Therapy, Diplo Runs...

PT402 – Magic, Virtual Reality, and Ketamine & Internal Family Systems

Numinus to Host Q2 2023 Results Conference Call on April 13,...

Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical...

Opinions | Why Reinvent the Wheel When You Can Amplify the...

1...969798...301Page 97 of 301

EDITOR PICKS

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA...

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©